You are here: Home / Programme

Scientific programme

5th Workshop on Emerging Issues in Oncogenic Virus Research
30 May to 3 June 2018


Arrival of participants
Check-in at Hotel dei Bizantini and registration
20:00–21:30
Concert, Chiostro Chiesa di San Francesco, Manduria
(transport by bus)
21:30–24:00
Dinner, Hotel Corte Borromeo, Manduria
08:30–10:00
Registration
09:20–09:30
Welcome Address
Session 1
09:30–12:40
Epidemiology
Chairpersons: Maria Gabriella DONÀ and Denise WHITBY
09:30–09:50
[O1]
Human papillomavirus infection and squamous cell carcinoma in organ transplant recipients
Jan Nico BOUWES BAVINCK
(The Netherlands)
09:50–10:10
[O2]
Cutaneous HPV infection, ultraviolet radiation exposure and risk of squamous cell carcinoma in the VIRUSCAN study
Dana ROLLISON
(USA)
10:10–10:30
[O3]
HPV-related malignancy in solid organ transplant patients
Marc GOODMAN
(USA)
10:30–10:50
[O4]
HPV antibody patterns in patients with HPV-driven cancers
Michael PAWLITA (Germany)
10:50–11:00
[O5]
Epidemiological risk factors for HPV16 E6 seropositivity in healthy individuals from the UK Biobank pilot study
Nicole BRENNER
(Germany)
11:00–11:20
Coffee break
11:20–11:30
[O6]
Prevalence of human papillomavirus antibodies and survival in people with head and neck cancer: results from Head and Neck 5000
Andy NESS
(Germany)
11:30–11:40
[O7]
The prevalence and prognostic value of HPV varies depending on oropharyngeal sub-site
Linnea HAEGGBLOM
(Sweden)
11:40–12:00
[O8]
Vaginal microbiome (VM) and associated cytokine and metabolome profiles in a prospective study of HPV 16 acquisition, persistence and clearance
Anna-Barbara MOSCICKI
(USA)
12:00–12:10
[O9]
Identification and characterization of two distinct subtypes of anal adenocarcinoma
Michael HERFS
(Belgium)
12:10–12:20
[O10]
Association of human leukocyte antigen alleles and Kaposi’s sarcoma (KS) in a case-control study from Cameroon
Elena M. CORNEJO CASTRO
(USA)
12:20–12:30
[O11]
Epidemiology of a novel putative human polyomavirus, LIPyV
Tarik GHEIT
(France)
12:30–12:40
[O11′]
Seroprevalence of fourteen human polyoma-viruses determined in a Dutch blood donor population
FELDKAMP M
(The Netherlands)
12:40–14:00
Lunch
Session 2
14:00–18:30
Immunology
Chairpersons: Géraldine SCHLECHT-LOUF and Sigrun SMOLA
14:00–14:20
[O12]
Roles of IL-17 and IkBzeta as mediators of Ras transformation in keratinocytes
Rosalba SALCEDO
(USA)
14:20–14:40
[O13]
Dysregulation of the innate immunity network as oncogenic strategy and novel therapeutic target for high-risk HPVs
Marisa GARIGLIO
(Italy)
14:40–14:50
[O14]
Mus musculus papillomavirus 1 infection of the female lower genital tract in mice deficient in key adaptor molecules involved in the interferon response
Fabiana CANNELLA
(Italy)
14:50–15:00
[O15]
Proper CXCR4 desensitization is required for skin immunosurveillance by dendritic cells in the course of papillomavirus-induced dysplasia
Géraldine SCHLECHT-LOUF
(France)
15:00–15:10
[O16]
Regulation of IFN-kappa expression in normal and HPV-positive keratinocytes by TGF-beta and ERK1/2
Frank STUBENRAUCH
(Germany)
15:10–15:30
[O17]
Myeloid cells and SIV/HIV acquisition
Genoveffa FRANCHINI
(USA)
15:30–15:40
[O18]
Immunoselective algorithm to devise multi-epitope subunit vaccine fighting against Epstein-Barr virus infection
Rajan Kumar PANDEY
(India)
15:40–16:00
[O19]
Hepatitis C virus persistence & a novel feed-back in innate immunity with possible links to cancer
Marco BINDER
(Germany)
16:00–16:20
Coffee break
16:20–16:40
[O20]
Progress towards clinical development of RG1-VLP, a broad-spectrum HPV candidate vaccine
Reinhard KIRNBAUER
(Austria)
16:40–17:00
[O21]
L2-based prophylactic vaccine against cutaneous HPV
Martin MÜLLER
(Germany)
17:00–17:20
[O22]
Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus
Richard RODEN
(USA)
17:20–17:30
[O23]
Getting rid of sarcoids – recombinant live-attenuated influenza viruses expressing BPV-1 E6 and E7 as novel therapeutic vaccine for horses
Christoph JINDRA
(Austria)
17:30–17:50
[O24]
Recent progress in the use of different biomarkers for predicting clinical outcome in human papillomavirus positive tonsillar and base of tongue cancer
Tina DALIANIS
(Sweden)
17:50–18:00
[O25]
Protein expression in tonsillar and base of tongue cancer and in relation to human papillomavirus (HPV) and clinical outcome
Torbjörn RAMQVIST
(Sweden)
18:00–18:10
[O26]
Medical (immuno)therapy of patients with HPV lesions: state of art
Aldo VENUTI
(Italy)
18:10–18:20
[O27]
Systematic analysis of KSHV specific T cell responses measured by IFN-γ ELISPOT using proteome-wide overlapping peptides and characterisation of T-cell clones
Denise WHITBY
(USA)
18:20–18:30
[O28]
Caspase activity contributes to evasion of early innate immune responses by Kaposi’s sarcoma-associated herpesvirus
Marta GAGLIA
(USA)
18:30–20:30
Poster session and flash talks (posters 1–19) with drinks
20:30
Dinner
Session 3
08:00–13:00
Virus–host interaction I
Chairpersons: Megan E. SPURGEON and Nicole FISCHER
08:00–08:20
[O29]
Intact human papillomavirus type 16 capsids mediate nuclear entry during infection
Patricia DAY
(USA)
08:20–08:40
[O30]
Regulation and execution of HPV16 endocytosis into host cells
Mario SCHELHAAS
(Germany)
08:40–09:00
[O31]
PML protein associates with incoming HPV genomes still residing in membrane-bound transport vesicles
Martin SAPP
(USA)
09:00–09:10
[O32]
Structural and functional analysis of HPV16 L2
Claudia SIMON
(Germany)
09:10–09:20
[O33]
Extracellular conformational changes in the capsid of human papillomaviruses contribute to asynchronous uptake into host cells
Miriam BECKER
(Germany)
09:20–09:30
[O34]
Non-filamentous vimentin protein binds to HPV16 pseudovirions and dampens infection in a murine model
Georgia SCHÄFER
(South Africa)
09:30–09:40
[O35]
Human papillomavirus life cycle: contribution of CXCR7 to the gatekeeper function of the CXCL12 chemokine
Carmen GALLEGO
(France)
09:40–10:00
[O36]
Regulation of the HPV life cycle by the DNA damage response
Cary MOODY
(USA)
10:00–10:20
[O37]
Sp100 restricts both initial and productive stages of the infectious HPV cycle
Alison McBRIDE
(USA)
10:20–10:40
Coffee break
10:40–11:00
[O38]
CTCF regulates the epigenetic landscape of the human papillomavirus enhancer to control differentiation-dependent early viral gene expression
Joanna PARISH
(UK)
11:00–11:20
[O39]
Preferential repair of E6/E7 induced breaks in viral genomes leads to amplification
Laimonis LAIMINS
(USA)
11:20–11:40
[O40]
Characterisation of human papillomavirus 18 E6 PDZ protein complexes in the virus life cycle
Sally ROBERTS
(UK)
11:40–12:00
[O41]
A novel link between inflammatory signalling and expansion of the stem cell compartment in HPV-driven carcinogenesis
Sigrun SMOLA
(Germany)
12:00–12:20
[O42]
Multiple interactions of E6 proteins across papillomavirus species: atomic and interatomic insights
Gilles TRAVÉ
(France)
12:20–12:30
[O43]
TIP60 keeps the endogenous oncogenic demons repressed
Sudhakar JHA
(Singapore)
12:30–12:50
[O44]
Gender-bias effects of HPV16 on the tonsil epithelial epigenome
Craig MEYERS
(USA)
12:50–13:00
[O45]
The role of Tax and antisense proteins in the HTLV deregulation of the NF-kB pathway
Umberto BERTAZZONI
(Italy)
13:00–15:00
Lunch
Session 4
15:00–19:10
Cellular transformation I
Chairpersons: Katerina STRATI and Michelle OZBUN
15:00–15:20
[O46]
Molecular mechanisms of Epstein-Barr virus oncogenesis
Maria G. MASUCCI
(Sweden)
15:20–15:40
[O47]
The role of Epstein-Barr virus in the pathogenesis of nasopharyngeal carcinoma: recent insights and novel therapies
Lawrence YOUNG
(UK)
15:40–15:50
[O48]
EBV leaves its mark: new evidence of “hit and run” hypothesis from non-conventional methods
Lucia MUNDO
(Italy)
15:50–16:10
[O49]
Mechanisms of genome persistence by oncogenic herpesviruses
Paul LIEBERMAN
(USA)
16:10–16:30
[O50]
Targeting the KSHV non-structural membrane protein pK15 to inhibit viral replication and pathogenesis
Thomas F. SCHULZ
(Germany)
16:30–16:50
[O51]
Interaction of the Merkel cell polyomavirus LT-antigen with host cell chromatin
Nicole FISCHER
(Germany)
16:50–17:10
Coffee break
17:10–17:30
[O52]
Does sunlight and Merkel cell polyomavirus target the same pathways in Merkel cell carcinoma?
James DeCAPRIO
(USA)
17:30–17:40
[O53]
Role of the Merkel cell polyomavirus (MCPyV) tumor antigens in tumor development
Megan E. SPURGEON
(USA)
17:40–17:50
[O54]
Characterization of biological properties of the novel human polyomavirus Lyon IARC PyV (LIPyV)
Assunta VENUTI
(France)
17:50–18:10
[O55]
The SUMO pathway during viral-mediated tumorigenesis
Susanna CHIOCCA
(Italy)
18:10–18:20
[O56]
Biological properties of human papillomavirus type 18 natural variants
Laura SICHERO
(Brazil)
18:20–18:30
[O57]
Reck downregulation plays a role in HPV associated carcinogenesis
Enrique BOCCARDO
(Brazil)
18:30–18:50
[O58]
Efficient transformation of human adult stem cells by adenovirus oncogenes
Thomas DOBNER (Germany)
18:50–19:00
[O59]
Adeno-associated virus infection in liver and consequence in tumor development
Tiziana LaBELLA
(France)
19:00–19:10
[O60]
BPV1 virions infect and transform equine fibroblasts in vitro
Edmund HAINISCH
(Austria)
20:00–23:30
Dinner
Local winery in Manduria (transport by bus)
Session 5
09:30–16:40
Virus–host interaction II
Chairpersons: Donna NEUMANN and Cary MOODY
09:30–09:50
[O61]
Split GFP assay detects protrusion of a segment of the HPV L2 protein through the endosomal membrane into the cytoplasm for sorting into the retrograde pathway during virus entry
Daniel DiMAIO
(USA)
09:50–10:00
[O62]
Comparative RNA-sequencing reveals that HPV16 E6*I, an E6-truncated isoform, modulates whole gene expression independently of E6
Philippe PAGET-BAILLY
(France)
10:00–10:10
[O63]
Microvesicles secreted by HPV-positive cervical cancer cell-lines promote proliferation and migration in primary foreskin fibroblasts
Christopher NGAN
(Australia)
10:10–10:30
[O64]
Structural analysis of antibodies targeting human polyomaviruses
Thilo STEHLE
(Germany)
10:30–10:50
[O65]
Imaging polyomavirus nuclear assembly “factories”
Robert GARCEA
(USA)
10:50–11:00
[O66]
Trichodysplasia spinulosa in a kidney transplant recipient with concurrent JC, BK, and TSPyV viruria and decoy or degenerated cells
Silvia ALBERTINI
(Italy)
11:00–11:10
[O67]
SV40 encapsidation results in the spread of histone modifications and sliding of nucleosomes in the chromatin
Barry MILAVETZ
(USA)
11:10–11:30
Coffee break
11:30–11:50
[O68]
JC polyomavirus uses extracellular vesicles to infect target cells
Walter J. ATWOOD
(USA)
11:50–12:10
[O69]
Paradoxical SCF E3 ligase regulation of small tumor virus latency and replication
Patrick MOORE
(USA)
12:10–12:30
[O70]
Initiation of MCC-like tumor development in mice co-expressing Merkel cell polyomavirus T antigens and ATOH1
Andrzej DLUGOSZ
(USA)
12:30–12:50
[O71]
MCPyV T antigens and their association with ubiquitin ligases
Denise GALLOWAY
(USA)
12:50–13:10
[O72]
Control of BKPyV mRNA and miRNA expression
Michael IMPERIALE
(USA)
13:10–13:20
[O73]
Quantitative temporal viromics (QTV) and cell cycle inhibition reveal BK polyomavirus (BKPyV) replication is dependent upon the activity of late phase cell cycle proteins
Laura CALLER
(UK)
13:20–15:00
Lunch
15:00–15:20
[O74]
Study of tumorviral microRNA biogenesis reveals a previously unknown hepatitis C virus (HCV) restriction factor
Christopher S. SULLIVAN
(USA)
15:20–15:40
[O75]
APOBEC3 mutagenesis, viral infection, and cancer
Christopher BUCK
(USA)
15:40–16:00
[O76]
An analog sensitive derivative of the Epstein Barr virus v-Cdk permits the direct identification of substrates participating in multiple stages of gene expression
Rob KALEJTA
(USA)
16:00–16:20
[O77]
Polycomb recruitment during herpesvirus latency establishment
Adam GRUNDHOFF
(Germany)
16:20–16:30
[O78]
Potential mode of Epstein Barr virus infection and emerging pathogenicity in various diseases
Hem C. JHA
(India)
16:30–16:40
[O79]
Virus-receptor interactions of the Kaposi’s sarcoma-associated herpesvirus and the related rhesus monkey rhadinovirus
Alexander S. HAHN
(Germany)
16:40–17:00
Coffee break
Session 6
17:00–18:40
Cellular transformation II
Chairpersons: Laura SICHERO and Joanna PARISH
17:00–17:20
[O80]
EGFR signalling is a nexus regulating HPV oncogene expression
Michelle OZBUN
(USA)
17:20–17:40
[O81]
Cutaneous papillomaviruses - from mice to men
Karl MUNGER
(USA)
17:40–17:50
[O82]
Enrichment of PI(4,5)P2 in HPV+ keratinocytes causes enhanced phospholipidation of nuclear proteins
Baki AKGÜL
(Germany)
17:50–18:00
[O83]
UV and cutaneous papillomavirus infection cooperate in non-melanoma skin cancer development
Daniel HASCHE
(Germany)
18:00–18:20
[O84]
Mouse papillomavirus pathogenesis: why don’t cutaneous papillomaviruses encode an E5 gene?
Paul F. LAMBERT
(USA)
18:20–18:30
[O85]
Human papillomavirus type 8 degrades checkpoint-kinase 1 by exerting control over the autophagy pathway
Martin HUFBAUER
(Germany)
18:30–18:40
[O86]
Malignant transformation of mammary epithelial cells by human cytomegalovirus
Georges HERBEIN
(France)
18:40–20:00
Poster session and flash talks (posters 20–37) with drinks
20:30
Social dinner
Departure – Shuttles to airport



ATWOOD, Walter J.
Department of Molecular Biology, Cell Biology, and Biochemistry
Brown University
70 Ship Street, Box GE434
Providence RI 02903
USA

BANKS, Lawrence
Tumour Virology Group
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Padriciano 99
34149 Trieste
Italy

BINDER, Marco
Division of Virus-associated Carcinogenesis (F170)
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

BOUWES BAVINCK, Jan Nico
Department of Dermatology
Leiden University Medical Center
2300 RC Leiden
Netherlands

BUCK, Christopher B.
Tumor Virus Molecular Biology Section
National Cancer Institute, NIH
9000 Rockville Pike, Bldg 37, Rm 4118
Bethesda MD 20892
USA

CHANG, Yuan
University of Pittsburgh Cancer Institute
5117 Centre Avenue, Res. Pav. 1.8
Pittsburgh PA 15213
USA

CHIOCCA, Susanna
Viral Control of Cellular Pathways and Biology of Tumorigenesis
European Institute of Oncology
Via Adamello 16
20139 Milan
Italy

DALIANIS, Tina
Department of Oncology-Pathology
Karolinska University Hospital
Cancer Center Karolinska, R8:01
171 76 Stockholm
Sweden

DAY, Patricia
Laboratory of Cellular Oncology
Center for Cancer Research, National Cancer Institute, NIH
Building 37, Room 4112
Bethesda MD 20892-4263
USA

DeCAPRIO, James
Department of Medical Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA 02215
USA

DiMAIO, Daniel
Department of Genetics
Yale School of Medicine
333 Cedar Street
New Haven CT 06510
USA

DLUGOSZ, Andrzej
Department of Dermatology
University of Michigan Medical School
1500 East Medical Center Drive, #1910
Ann Arbor MI 48109
USA

DOBNER, Thomas
Heinrich Pette Institute
Leibniz Institute for Experimental Virology
Martinistraße 52
20251 Hamburg
Germany

EHLERS, Bernhard
Division of Viral Infections
Robert Koch Institute
Seestraße 10, Box 650261
13302 Berlin
Germany

FISCHER, Nicole
University Medical Center Hamburg-Eppendorf
Martinistrasse 52
20246 Hamburg
Germany

FRANCHINI, Genoveffa
Animal Models and Retroviral Vaccines Section
Center for Cancer Research, National Cancer Institute, NIH
9000 Rockville Pike
Bethesda MD 20892
USA

GALLOWAY, Denise
Microbiology
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North
Seattle WA 98104
USA

GARCEA, Robert L.
Department of Molecular, Cellular & Developmental Biology, BioFrontiers Institute
University of Colorado at Boulder
Jennie Smoly Caruthers Biotechnology Bldg, Rm D212
Campus Box 596
Boulder CO 80309-0596
USA

GARIGLIO, Marisa
Department of Clinical and Experimental Medicine
University of Piemonte Orientale A. Avogadro
Via Solaroli 17
28100 Novara
Italy

IMPERIALE, Michael J.
Microbiology & Immunology
University of Michigan Medical School
1150 West Medical Center Drive
Ann Arbor MI 48109
USA

KIRNBAUER, Reinhard
Department of Immunodermatology
Medical University Vienna
Währinger Gürtel 18-20
1090 Vienna
Austria

LAIMINS, Laimonis
Department of Microbiology-Immunology
Northwestern University
303 East Chicago Avenue
Ward 8-296
Chicago IL 60611
USA

LAMBERT, Paul F.
McArdle Laboratory for Cancer Research
University of Wisconsin School of Medicine and Public Health
1400 University Avenue
Madison WI 53706-15991
USA

MASUCCI, Maria G.
Department of Cell and Molecular Biology
Karolinska Institutet
Berzelius väg 35, Box 285
171 77 Stockholm
Sweden

McBRIDE, Alison
DNA Tumor Virus Section, Laboratory of Viral Diseases
National Institute of Allergy and Infectious Diseases, NIH
33 North Drive, Building 33, Room 3W20
Bethesda MD 20892-3209
USA

MOODY, Cary
Department of Microbiology and Immunology
University of North Carolina
125 Mason Farm Road, 6th Floor Marsico Hall
Chapel Hill NC 27599-7290
USA

MOORE, Patrick S.
University of Pittsburgh Cancer Institute
5117 Centre Avenue, Res. Pav. 1.8
Pittsburgh PA 15213
USA

MOSCICKI, Anna-Barbara
University of California, Los Angeles
10833 Le Conte Avenue, MD 22-432
Los Angeles CA 90095-1752
USA

MÜLLER, Martin
Tumorvirus-specific Vaccination Strategies (F035)
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 242
69120 Heidelberg
Germany

MÜNGER, Karl
Department of Developmental, Molecular & Chemical Biology
Tufts University School of Medicine
150 Harrison Avenue, J607
Boston MA 02111
USA

OZBUN, Michelle
Department of Molecular Genetics & Microbiology
MSC08 4660
University of New Mexico School of Medicine
Albuquerque NM 87131
USA

PARISH, Joanna
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
Vincent Drive
Birmingham B15 2TT
United Kingdom

PAWLITA, Michael
Division of Genome Modifications and Carcinogenesis, Infection and Cancer Program
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

RODEN, Richard
Department of Pathology
Johns Hopkins University
1550 Orleans Street
Baltimore MD 21287
USA

ROLLISON, Dana
Department of Cancer Epidemiology
H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive, MRC-CANCONT
Tampa FL 33612-9416
USA

SALCEDO, Rosalba
Cancer and Inflammation Program
Center for Cancer Research
National Cancer Institute
37 Convent Drive
Bethesda, MD 20892
USA

SAPP, Martin
Feist-Weiller Cancer Center
LSU Health Sciences Center Shreveport
1501 Kings Highway, Box 33932
Shreveport LA 71130
USA

SCHELHAAS, Mario
Emmy-Noether Group: Virus Endocytosis
Institutes of Molecular Virology and Medical Biochemistry
ZMBE, University of Münster
Von-Esmarch-Straße 56
48147 Münster
Germany

SCHULZ, Thomas
Virology
Hannover Medical School
Carl-Neuberg-Straße 1
30625 Hannover
Germany

SMOLA, Sigrun
Institute of Virology
Saarland University
Kirrberger Straße, Haus 47
66421 Homburg
Germany

STEHLE, Thilo
Interfaculty Institute of Biochemistry
University of Tübingen
Hoppe-Seyler-Straße 4
72076 Tübingen
Germany

SULLIVAN, Christopher
Department of Molecular Biosciences
University of Texas at Austin
2506 Speedway, A5000
Austin TX 78712
USA

TRAVÉ, Gilles
Institut de recherche de l’Ecole de biotechnologie de Strasbourg
UMR 7242 CNRS, University of Strasbourg
ESBS, 300 Bd Sébastien Brant, BP 10413
67412 Strasbourg
France

YOU, Jianxin
Department of Microbiology
Perelman School of Medicine at the University of Pennsylvania
201C Johnson Pavilion, 3610 Hamilton Walk
Philadelphia PA 19104-6076
USA
Poster Sessions
Thursday 31 May 2018, 18:30–20:30;
Saturday 2 June 2018, 18:40–20:00
P01
The HPV-18 E7 CKII phospho acceptor site is required for maintaining the transformed phenotype of cervical tumour derived cells
Om BASUKALA
(Italy)
P02
HPV testing and cytology of fine-needle aspirates from cervical lymph node metastasis of patients with head and neck cancer
Maria BENEVOLO
(Italy)
P03
The contribution of KSHV inflammatory cytokine syndrome (KICS) to mortality of HIV patients in South Africa
Melissa BLUMENTHAL (South Africa)
P04
Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types
Rosario BRANCACCIO
Alexis ROBITAILLE
(France)
P05
Deciphering the radiosensitivity of HPV positive tumors
Diane BRUYERE (Belgium)
P06
A novel in vitro model for studying cutaneous papillomavirus–host interactions
Rui CAO (Germany)
P07
Detection of high-risk HPV DNA and mRNA, and p16/ki67 expression in anal samples of individuals at risk for anal cancer
Maria Gabriella DONÀ (Italy)
P8
A plant signal sequence enhances the therapeutic efficacy of a chimeric E7-L2 based DNA vaccine for HPV-associated cancers
Rosella FRANCONI (Italy)
P9
Detection of HPV16 variants circulating in the Calabria Region by sequencing of the Long Control Region (LCR) and the L1, E6 and E7 genes
Luisa GALATI
Paola DiBONITO
(Italy)
P10
The role of histone deacetylase 6 in late phase of mouse polyomavirus infection
Lenka HORNIKOVA (Czech Republic)
P11
A conserved lysine residue within CRPV E2 affects subcellular localization of either E1 and/or E2
Thomas IFTNER (Germany)
P12
Characterization of extracellular vesicles of HPV-positive cancer cells
Marco IULIANO (Italy)
P13
Transcript characterization of a novel gammaherpesvirus long noncoding RNA (lncRNA)
Mehmet KARA (Turkey)
P14
Detection of human papillomavirus and Chlamydia trachomatis in pregnant women in Córdoba, Argentina
Ana Ximena KIGUEN (Argentina)
P15
The role of BK polyomavirus (BKPyV) minor capsid proteins, Vp2 and Vp3, in viral entry
Elias Myrvoll LORENTZEN
Christine Hanssen RINALDO
(Norway)
P16
Acceptability of cervicovaginal self-sampling in cervical cancer screening
Noely LORENZI (Brazil)
P17
Biomarkers in cervicovaginal self-sampling for pre-neoplastic lesions and cervical cancer
Noely LORENZI (Brazil)
P18
Characterization of four Merkel cell carcinomas (MCC) with local relapse and one MCC with lymph node metastasis alongside with matching MCC- and dermis-derived fibroblasts
Licia MARTUSCELLI (Italy)
P19
Hairy root cultures for the bioproduction of a HPV therapeutic vaccine
Silvia MASSA (Italy)
P20
Ubc9 regulation in HPV-induced carcinogenesis: the role of HPV16 E7
Alessandro MEDDA (Italy)
P21
Sexually transmitted infections in oral cavity lesions: human papillomavirus, Chlamydia trachomatis and herpes simplex virus
Jessica MOSMANN (Argentina)
P22
HCMV persistence enhances activation of the STAT3 pathway in glioblastoma cells
Donna NEUMANN (USA)
P23
HPV-induced field cancerisation: the basis of adult tissue stem cell conversion into cancer stem cell
Carlotta OLIVERO (UK)
P24
Targeting heparan sulfonated proteoglycans as a means to prevent human papillomavirus infections
Michelle OZBUN (USA)
P25
The role of OCT4 in HPV-positive cervical cancers
Theofano PANAYIOTOU (Cyprus)
P26
Human papillomavirus expression in patients with skin tags
Francesca PAOLINI (Italy)
P27
Regulation of PKR expression by HSV-1: potential approach in cancer therapy
Rosamaria PENNISI (Italy)
P28
Detection of human papillomavirus DNA and mRNA in oral rinse-and-gargles of men who have sex with men: the OHMAR project
Francesca ROLLO (Italy)
P29
HPV38 induces ITGA-1 downregulation via p53 to promote cell proliferation
Maria Carmen ROMERO MEDINA (France)
P30
The SUMO conjugating enzyme Ubc9 in HPV positive head and neck squamous cell carcinoma
Maria Elisa SABATINI (Italy)
P31
Linking HPV E6 PBM promiscuity and acquisition of a phospho-acceptor site
Vanessa SARABIA (Italy)
P32
Human papillomavirus 16 infection induces VAP-dependent endosomal tubulation
Abida SIDDIQA (Italy)
P33
Proteomic analysis of ΔNp73α and p53 in human foreskin keratinocytes immortalized with HPV38 E6/E7
Valerio TAVERNITI (France)
P34
Role of chronic inflammation and oxidative stress in HPV-mediated cell transformation
Lara TERMINI (Brazil)
P35
A naturally occurring variant of HPV-16 E7 exerts increased transforming activity acquisition of an additional phospho-acceptor site
Vjekoslav TOMAIĆ (Croatia)
P36
Characterization of E1C, a diagnostically relevant human papillomavirus16 protein
Christy Susan VARGHESE (Germany)
P37
Validation of a stable, ready-to-use ELISA to detect HPV16 E6 antibodies in OPSCC patients and controls
Daniele VIARISIO (Germany)